Clinical trial · Observational
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT of Patients in Complete Remission of Malignant Lymphoma
NCT04464590CI-TRIAL-00045890LYMPHOTEP1completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the study, we aimed to characterize the role of FDG PET/CT surveillance at 12 months of malignant lymphoma in asymptomatic patients after a first complete remission and to define a rational follow-up strategy.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diagnostic Imaging | — | UNRESOLVED | — |
| Malignant Lymphoma | Lymphoma | ALIAS | 0.90 |
| Relapsed Hodgkin's Disease, Adult | Adult Hodgkin Lymphoma | ALIAS | 0.85 |
| Relapsed Non Hodgkin Lymphoma | Non-Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- role of FDG-PET/CT surveillance at 12months of lymphoma in asymptomatic patient in first complete remission
- timeFrame
- one day
- description
- detection rate of relapse at 1 year and at the end of follow-up
- measure
- performances FDG-PET/CT 1 year
- timeFrame
- one day
- description
- sensitivity, sensibility, predictive negative value, predictive positive value, accuracy
Secondary outcomes (1)
- measure
- overall survival and progression-free survival
- timeFrame
- one day
- description
- as the time from the end of first-line chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * first diagnosis of aggressive lymphoma, complete metabolic remission after a first-line of chemotherapy, no relapse in the first year after the end of treatment Exclusion Criteria: * minor patient, pregnant woman, legal protection (legal curatorship / guardianship), absence of consent
References
Publications (0)
Data not yet available
No reference posted for this study.